"The U.S. Food and Drug Administration recently approved Oralair to treat allergic rhinitis (hay fever) with or without conjunctivitis (eye inflammation) that is induced by certain grass pollens in people ages 10 through 65 years. Oralair is the f"...
AllerNaze Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
AllerNaze (triamcinolone acetonide) Nasal Spray is a corticosteroid used to treat the nasal symptoms of seasonal and perennial allergic rhinitis in adults and children 12 years of age or older. The brand name of this medication is discontinued, but generic versions may be available. Common side effects include application site reaction (nasal burning and stinging), runny or stuffy nose, menstrual pain, and allergic reactions.
The recommended starting dose of AllerNaze for most patients is 200 mcg per day given as 2 sprays (approximately 50 mcg/spray) in each nostril once a day. AllerNaze may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, AllerNaze should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our AllerNaze (triamcinolone acetonide) Nasal Spray Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
AllerNaze FDA Prescribing Information: Side Effects
In adequate, well-controlled and uncontrolled studies, 1187 patients have received triamcinolone acetonide solution. The adverse reactions summarized below, are based upon seven placebo controlled clinical trials of 2-6 weeks duration in 847 patients with seasonal or perennial allergic rhinitis (504 patients received 200 mcg or 400 mcg per day of triamcinolone acetonide solution and 343 patients received vehicle placebo). Adverse events reported by 2% or more of patients (regardless of relationship to treatment) who received triamcinolone acetonide solution 200 or 400 mcg once daily and that were more common with triamcinolone acetonide solution than with placebo are displayed in the table below. Overall, the incidence and nature of adverse events with triamcinolone acetonide solution 400 mcg was comparable to that seen with triamcinolone acetonide solution 200 mcg and with vehicle placebo.
ADVERSE EVENTS REPORTED AT A FREQUENCY OF 2% OR GREATER AND
MORE COMMON AMONG PATIENTS TREATED WITH triamcinolone acetonide solution THAN
PLACEBO REGARDLESS OF RELATIONSHIP TO TREATMENT
|ADVERSE EVENTS||200 mcg of
n = 204
|400 mcg of
n = 300
(200 and 400 mcg)
use of triamcinolone
n = 504
n = 343
|BODY AS A WHOLE|
Adverse events reported by 2% or more of patients who received triamcinolone acetonide solution 200 or 400 mcg once daily and that were more common with placebo than with triamcinolone acetonide solution included: application site reaction (e.g. transient nasal burning and stinging), rhinitis, dysmenorrhea, pain (unspecified) and allergic reaction.
The adverse effects related to the irritation of nasal mucous membranes (i.e. application site reaction) did not usually interfere with treatment. In the controlled and uncontrolled studies, approximately 0.3% of patients discontinued because of irritation of nasal mucous membranes.
Read the entire FDA prescribing information for AllerNaze (Triamcinolone Acetonide Nasal Spray)
Additional Allernaze Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.